Healthcare ❯ Pharmaceuticals

Clinical Trials

Drug Development Drug Safety Cancer Treatment Pulmonary Arterial Hypertension Weight Loss Drugs Efficacy Studies Rare Diseases Drug Efficacy Vaccine Development Mental Health

Gossamer Bio Hit With Investor Class Action After PROSERA Miss, With June 1 Lead‑Plaintiff Deadline

Plaintiff firms are urging investors to seek lead‑plaintiff status by the June 1 deadline.

Regeneron Slides as Melanoma Combo Fails to Beat Keytruda in Phase 3

HCW Biologics Posts Surprise Q1 Profit on Trimmune Deal as Listing Risk Lingers

Cormedix Lifts 2026 Outlook After Q1 Beat, Sets H2 FDA Filing Plan for Rizzeo

Verrica Reports $5 Million Q1 Revenue as Wycanth Grows and Phase 3 Wart Program Advances

Gossamer Bio Faces Securities Class Action After PROSERA Failure, 80% Stock Plunge

Personalized mRNA Vaccine Shows Durable Survival Signal in Early Pancreatic Cancer

Law Firms Press Soleno Investors to Seek Lead Role in Securities Suit by May 5

Soleno Faces Securities Class Action Over DCCR Safety as Investors Weigh May 5 Lead‑Plaintiff Deadline

Law Firms Seek Ultragenyx Investors to Lead Securities Class Actions After OI Trial Miss

Soleno Hit With Securities Class Action Over Prader‑Willi Drug DCCR

Soleno Therapeutics Sued in Federal Securities Class Action Over DCCR Safety Disclosures

Structure’s Oral Obesity Pill Delivers 16.3% Placebo-Adjusted Weight Loss in Phase 2

Brazil Nears Semaglutide Patent Expiry as Anvisa Reviews 14 Filings and Novo Nordisk Counters

Zealand Plunges as Roche Obesity Drug Posts 10.7% Weight Loss With Placebo‑Like Tolerability

Mereo BioPharma Investors Face April 6 Deadline in Lawsuits Over Failed Setrusumab Trials

Roche’s CT-388 Shows Up to 22.5% Placebo-Adjusted Weight Loss in Phase 2 as Phase 3 Nears

Relief Rally Ebbs After Trump Halts Tariff, Military Threats Over Greenland

Moderna, Merck Melanoma Vaccine Shows Durable Five-Year Benefit as Stock Hits 52-Week High

J&J Beats Q4 Forecasts and Sets 2026 Guidance Above Wall Street